Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Similar articles for PubMed (Select 20103744)

1.

Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.

Hare KJ, Vilsbøll T, Holst JJ, Knop FK.

Am J Physiol Endocrinol Metab. 2010 Apr;298(4):E832-7. doi: 10.1152/ajpendo.00700.2009. Epub 2010 Jan 26.

2.

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.

Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK.

Am J Physiol Endocrinol Metab. 2011 Jun;300(6):E1038-46. doi: 10.1152/ajpendo.00665.2010. Epub 2011 Mar 8.

3.
4.

Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance.

Lanng S, Thorsteinsson B, Røder ME, Orskov C, Holst JJ, Nerup J, Koch C.

Acta Endocrinol (Copenh). 1993 Mar;128(3):207-14.

PMID:
8480468
5.

Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.

Hare KJ.

Dan Med Bull. 2010 Sep;57(9):B4181.

PMID:
20816021
7.

Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus.

Cypryk K, Vilsbøll T, Nadel I, Smyczyńska J, Holst JJ, Lewiński A.

Gynecol Endocrinol. 2007 Jan;23(1):58-62.

PMID:
17484514
8.

Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.

Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK.

J Clin Endocrinol Metab. 2010 Jul;95(7):3309-17. doi: 10.1210/jc.2010-0119. Epub 2010 Apr 21.

PMID:
20410219
9.

Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.

Fukase N, Manaka H, Sugiyama K, Takahashi H, Igarashi M, Daimon M, Yamatani K, Tominaga M, Sasaki H.

Acta Diabetol. 1995 Oct;32(3):165-9.

PMID:
8590785
10.

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.

Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ.

Diabetes. 2008 Mar;57(3):678-87. Epub 2007 Dec 5.

11.

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

Knop FK, Aaboe K, Vilsbøll T, Vølund A, Holst JJ, Krarup T, Madsbad S.

Diabetes Obes Metab. 2012 Jun;14(6):500-10. doi: 10.1111/j.1463-1326.2011.01549.x. Epub 2012 Jan 17.

PMID:
22171657
12.

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.

Diabetologia. 1996 Dec;39(12):1546-53.

PMID:
8960841
13.

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects.

Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA.

Diabetologia. 2007 Apr;50(4):806-13. Epub 2007 Feb 16.

PMID:
17334652
15.

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ.

Regul Pept. 2004 Nov 15;122(3):209-17.

PMID:
15491793
17.

Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.

Fukase N, Igarashi M, Takahashi H, Manaka H, Yamatani K, Daimon M, Tominaga M, Sasaki H.

Diabet Med. 1993 Jan-Feb;10(1):44-9.

PMID:
8435987
18.

Relationships between insulin secretion after intravenous and oral glucose administration in subjects with glucose tolerance ranging from normal to overt diabetes.

Mari A, Tura A, Pacini G, Kautzky-Willer A, Ferrannini E.

Diabet Med. 2008 Jun;25(6):671-7. doi: 10.1111/j.1464-5491.2008.02441.x.

PMID:
18544104
19.

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

Meier JJ, Gallwitz B, Askenas M, Vollmer K, Deacon CF, Holst JJ, Schmidt WE, Nauck MA.

Diabetologia. 2005 Sep;48(9):1872-81. Epub 2005 Jul 12.

PMID:
16010522
20.

Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals.

Bagger JI, Knop FK, Lund A, Holst JJ, Vilsbøll T.

Diabetologia. 2014 Aug;57(8):1720-5. doi: 10.1007/s00125-014-3264-2. Epub 2014 May 31.

PMID:
24879388
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk